Philadelphia, PA (PRWEB) June 6, 2008
James Ronca, shareholder at law firm Anapol, Schwartz, Weiss, Cohan, Feldman and Smalley, P.C., was recently appointed co-lead counsel of the national Trasylol® litigation's 12-member plaintiffs' steering committee in an Order issued by the Federal District Court for the Southern District of Florida. Ronca will be representing more than 30 victims, both in local courts and in the national litigation. At present, about 50 cases have been consolidated for pre-trial proceedings and trials by The Multi-District Litigation Panel in The Southern District of Georgia. The steering committee anticipates the filing of 500 additional cases.
Bayer AG's blood-preserving drug Trasylol® is administered by an anesthesiologist during coronary artery bypass graft (CABG) procedures to limit bleeding. Plaintiffs allege Trasylol® causes kidney/renal failure typically within 72 hours of surgery and increases mortality risk. Many, however, are unaware they have received the drug, complicating diagnosis. After 14 years on the market, Bayer suspended marketing in November, 2007 and pulled Trasylol® entirely in May, 2008 in response to FDA concerns.
Ronca has served as plaintiffs' counsel in many complex pharmaceutical and products liability cases involving Baycol, LOTRONEX, hormone replacement therapy and breast implants.
Founded in 1977, Anapol, Schwartz, Weiss, Cohan, Feldman & Smalley is a personal injury firm with 25 attorneys and law offices in Philadelphia, Media, Reading and Harrisburg, Pa., as well as Cherry Hill, N.J. The firm has a multi-faceted practice with a tradition of excellence in medical malpractice law, pharmaceutical mass tort, medical device matters, toxic tort, class actions, products liability, automobile, investor claims and wrongful termination litigation.
Editor's Note: Ronca is a graduate of Leigh University (B.A., with honors, 1974) and The Dickinson School of Law (J.D., 1977). He maintains residences in both Center City Philadelphia and Harrisburg, Pa.